Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020

Andreas Obermair; Philip Beale; Clare L Scott; Victoria Beshay; Ganessan Kichenadasse; Bryony Simcock; James Nicklin; Yeh Chen Lee; Paul Cohen; Tarek Meniawy

doi:10.3802/jgo.2021.32.e95

Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020

J Gynecol Oncol. 2021 Nov;32(6):e95. doi: 10.3802/jgo.2021.32.e95.

Authors

Andreas Obermair¹, Philip Beale^{2

3

4}, Clare L Scott^{5

6}, Victoria Beshay⁷, Ganessan Kichenadasse^{8

9}, Bryony Simcock¹⁰, James Nicklin^{11

12}, Yeh Chen Lee^{13

14

15}, Paul Cohen^{16

17}, Tarek Meniawy^{18

19}

Affiliations

¹ Queensland Centre for Gynaecological Cancer Research, The University of Queensland, Brisbane, QLD, Australia. a.obermair@uq.edu.au.
² Department of Medical Oncology Concord Hospital, Concord, NSW, Australia.
³ Department of Medical Oncology Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
⁴ Faculty of Medicine University of Sydney, Camperdown, NSW, Australia.
⁵ Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
⁶ Australia and Royal Women's Hospital, Parkville, VIC, Australia.
⁷ Molecular Diagnostic Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁸ Flinders Centre for Innovation in Cancer, Flinders Medical centre/Flinders University, Bedford Park, SA, Australia.
⁹ South Australian Cancer Clinical network, Commission for excellence and innovation in health, Citicentre building Adelaide, SA, Australia.
¹⁰ Canterbury District Health Board. University of Otago, Dunedin, New Zealand.
¹¹ Gynaecological Oncology, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
¹² Faculty of Medicine, The University of Queensland, St Lucia, QLD, Australia.
¹³ Prince of Wales and Royal Hospital for Women, Randwick, NSW, Australia.
¹⁴ NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia.
¹⁵ Faculty of Medicine, University of New South Wales, NSW, Australia.
¹⁶ Department of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, WA, Australia.
¹⁷ Division of Obstetrics and Gynaecology, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, WA, Australia.
¹⁸ Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
¹⁹ School of Medicine, University of Western Australia, Nedlands, WA, Australia.

Abstract

Epithelial ovarian cancer (EOC) is among the top ten causes of cancer deaths worldwide, and is one of the most lethal gynecological malignancies in high income countries, with incidence and death rates expected to rise particularly in Asian countries where ovarian cancer is among the 5 most common cancers. Despite the plethora of randomised clinical trials investigating various systemic treatment options in EOC over the last few decades, both progression-free and overall survival have remained at approximately 16 and 40 months respectively. To date the greatest impact on treatment has been made by the use of poly (ADP-ribose) polymerase (PARP) inhibitors in women with advanced EOC and a BRCA1/2 mutation. Inhibition of PARP, the key enzyme in base excision repair, is based on synthetic lethality whereby alternative DNA repair pathways in tumor cells that are deficient in homologous recombination is blocked, rendering them unviable and leading to cell death. The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the national gynecological cancer clinical trials organization for Australia and New Zealand. ANZGOG's purpose is to improve outcomes and quality of life for women with gynecological cancer through cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynecological cancer. This review summarizes current ovarian cancer research and treatment approaches presented by Australian and New Zealand experts in the field at the 2020 ANZGOG webinar series entitled "Ovarian Cancer systems of Care".

Keywords: BRCA1/2 Mutation; High-Grade Serous Ovarian Cancer; Homologous Recombination Deficiency; Neoadjuvant Chemotherapy; Ovarian Cancer; PARP Inhibitors.

Publication types

Review

MeSH terms

Australia
Carcinoma, Ovarian Epithelial
Female
Genital Neoplasms, Female* / drug therapy
Humans
Ovarian Neoplasms* / drug therapy
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Quality of Life

Substances

Poly(ADP-ribose) Polymerase Inhibitors